Back to Lung Cancer

NCT04866017

NCT04866017
Terminated Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You must be 18 years old or older (or meet the legal age of consent in your country) at the time of signing the consent form.
  • You must have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, Stage III) that cannot be removed by surgery, confirmed through a tissue or cell sample.
  • You must have already completed at least 2 rounds of a platinum-based chemotherapy given at the same time as radiation therapy.
  • Your lung cancer must not have gotten worse during or after that combined chemotherapy and radiation treatment.
  • You must be generally well enough to carry out daily activities, with only mild limitations at most (confirm with trial site).
  • Your liver, kidneys, and other organs must be working well enough as shown by blood tests (confirm with trial site).
  • You must be willing to provide a stored tumor tissue sample, or have a new tissue sample taken before treatment if no stored sample is available, so researchers can test it.

Who may not be able to join:

  • You have previously received certain immunotherapy drugs that target specific immune system pathways, such as anti-PD-1 or anti-PD-L1 treatments (confirm with trial site).
  • Your lung cancer has certain specific gene mutations or changes, including EGFR, ALK, ROS1, or RET (confirm with trial site).
  • You received any other cancer treatments beyond the combined chemotherapy and radiation therapy described above.
  • You are still experiencing side effects of Grade 3 or higher from your previous chemotherapy and radiation treatment (confirm with trial site).
  • You have an active autoimmune disease, or a history of one that could come back.
  • You have needed to take moderate-to-high doses of steroid medications or other immune-suppressing drugs within the last 14 days before starting the trial.
  • You have had an active infection requiring antibiotic, antifungal, or antiviral treatment within the last 14 days — though ongoing antiviral treatment for chronic hepatitis B or C is allowed.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 3
Sponsor
BeiGene
Registry
clinicaltrials_gov
Start date
17 June 2021
Est. completion
17 October 2023

Where this trial is recruiting

🇦🇺 Australia 🇨🇳 China 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov